SystImmune / Sichuan Biokin
SystImmune developed iza-bren, the first bispecific ADC to win a phase 3 trial.
Izalontamab brengitecan (EGFR×HER3), partnered with BMS for up to $8.4B; pipeline of further bispecific ADCs.
Izalontamab brengitecan is the first bispecific ADC to succeed in a phase 3 trial, hitting two growth receptors at once in triple-negative breast cancer.
SystImmune's HER2 ADC, sharing its payload with iza-bren, now in a 1,450-patient trial to replace Kadcyla after surgery.
Pages like this
not linked directly; found by shared links- TrialBL-B01D1-307
Shares Izalontamab brengitecan, Bispecific ADC, Oesophageal cancer, Triple-negative breast cancer (TNBC).
- TrialPANKU-Esophagus01 (BL-B01D1-305)
Shares Izalontamab brengitecan, Bispecific ADC, Oesophageal cancer.
- TrialDESTINY-Breast05
Shares Trastuzumab brengitecan, HER2-positive breast cancer.
- TrialIZABRIGHT-Breast01
Shares Izalontamab brengitecan, Triple-negative breast cancer (TNBC).
- TargetHER3
Shares Izalontamab brengitecan, Bispecific ADC, HER2-positive breast cancer, Oesophageal cancer.
- ProductToripalimab
Shares Li Zhang, Oesophageal cancer.
- ProductPegulicianine
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- PersonSara López-Tarruella
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC).